Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cefadroxil
Drug ID BADD_D00379
Description Long-acting, broad-spectrum, water-soluble, cephalexin derivative.
Indications and Usage For the treatment of the following infections (skin, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staphylococci and Streptococcus pyogenes
Marketing Status approved; vet_approved; withdrawn
ATC Code J01DB05
DrugBank ID DB01140
KEGG ID D00257; D02353
MeSH ID D002434
PubChem ID 47965
TTD Drug ID D0X9ZC
NDC Product Code 16714-390; 43063-553; 57237-096; 57237-098; 63629-7987; 63629-8253; 66267-045; 68180-180; 68788-8479; 65862-359; 16714-389; 72189-445; 80425-0198; 65862-085; 50090-6050; 63629-7988; 68180-182; 68071-5234; 16714-388; 45865-503; 63187-883; 68071-2752; 70518-2538; 50090-0580; 57237-097; 68788-7484; 68788-8261; 0093-3196; 0093-4059; 43063-595; 65862-083; 65862-084; 70518-3580; 72189-103; 50090-6356; 55289-589; 68180-181; 67296-1038; 68071-2938; 53002-2290
UNII 280111G160
Synonyms Cefadroxil | Cephadroxyl | Cefadroxil Anhydrous | 5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((amino(4-hydroxyphenyl)acetyl)amino)-3-methyl-8-oxo-, (6R-(6alpha,7beta(R*)))- | Ultracef | Bidocef | Duricef | BL-S 578 | BL S 578 | BLS 578 | BL-S578 | BL S578 | BLS578 | S-578 | S 578 | S578 | 4-Hydroxycephalexin | 4 Hydroxycephalexin | Cefadroxil Monohydrate
Chemical Information
Molecular Formula C16H17N3O5S
CAS Registry Number 50370-12-2
SMILES CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Serum sickness12.02.08.004; 10.01.03.004--
Somnolence19.02.05.003; 17.02.04.006--
Stevens-Johnson syndrome11.07.01.005; 10.01.01.045; 23.03.01.007; 12.03.01.014--
Superinfection11.01.08.009--Not Available
Swelling08.01.03.015--Not Available
Tension19.06.02.005--Not Available
Thrombocytopenia01.08.01.002--Not Available
Toxic epidermal necrolysis10.01.01.006; 23.03.01.008; 12.03.01.015; 11.07.01.0060.001394%
Tremor17.01.06.0020.000558%
Urticaria23.04.02.001; 10.01.06.0010.000558%
Vaginal infection11.01.10.002; 21.14.02.002--
Vertigo17.02.12.002; 04.04.01.003--
Vomiting07.01.07.003--
Mental status changes19.07.01.0010.000558%Not Available
Emotional distress19.04.02.0080.000558%Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Transaminases increased13.03.04.036--Not Available
Haemorrhage24.07.01.002--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Coombs test positive13.01.01.002--Not Available
Renal impairment20.01.03.010--Not Available
Drug reaction with eosinophilia and systemic symptoms12.03.01.064; 23.03.05.005; 10.01.01.0210.003345%Not Available
Cross sensitivity reaction10.01.01.0360.005575%Not Available
Vulvovaginal inflammation21.14.02.014--Not Available
The 3th Page    First    Pre   3    Total 3 Pages